Methods of modulating angiogenesis
AssigneeJoslin Diabetes Center, Inc.
InventorGeorge L. King
Life of this patent
Estimating the term…
Abstract
Featured are methods of modulating angiogenesis, e.g., by modulating PKC delta. The methods are useful in the treatment of disorders characterized by aberrant and/or increased blood vessel formation and/or increased permeability. The methods are also useful for treatment a disorder characterized by abnormal, inadequate or unstable blood vessel formation or increased permeability. Also featured are diagnostic and screening methods.
Claims18
A method of modulating angiogenesis in a cell, tissue, or subject, comprising modulating a PKC delta.
The method of claim 9, wherein the PKC delta agonist is selected from the group of:
- PKC delta polypeptide or functional fragment or analog thereof;
- a nucleic acid sequence encoding a PKC delta polypeptide or a functional fragment or analog thereof;
- and an agent which increases PKC delta expression.
A method of determining if a subject is at risk for a disorder characterized by abnormal or inadequate blood vessel formation, comprising:
- detecting, the presence or absence of a genetic lesion in a PKC delta gene, wherein the presence of a genetic lesion in the PKC delta gene is indicative of risk for a disorder characterized by abnormal or inadequate blood vessel formation.
A method of determining if a subject is at risk for a disorder characterized by abnormal or inadequate blood vessel formation, comprising:
- determining the expression levels of the PKC delta in the sample of cells, wherein reduced expression of PKC delta as compared to levels of PKC delta expression in a normal subject is indicative of risk for a disorder characterized by abnormal or inadequate blood vessel formation.
A method for identifying a compound capable of promoting angiogenesis, comprising:
- contacting a cell capable of expressing a PKC delta polypeptide with a test compound;
- and determining the level of PKC delta polypeptide or nucleic acid expression, wherein a compound capable of increasing PKC delta polypeptide or nucleic acid expression is indicative of a compound capable of promoting angiogenesis.
A method for identifying a compound capable of inhibiting angiogenesis, comprising:
- contacting a cell capable of expressing a PKC delta polypeptide with a test compound;
- and determining the level of PKC delta polypeptide or nucleic acid expression, wherein a compound capable of inhibiting PKC delta polypeptide or nucleic acid expression is indicative of a compound capable of inhibiting angiogenesis.
Dependencies are inferred from the claim text.